Criteria: Must be diagnosed with wAMD (wet age-related macular degeneration (also referred to as neovasular or exudative) Must have received treatments with intravitreal (IVT) injections into the eye (either Avastin®(bevacizumab), Lucentis® (ranibuzumab), Eylea® (aflibercept), Vabysmo™ (faricimab) or Anti-VEGF, or Port Delivery System (Susvimo®) Details: Participation: 60-minute anonymous webcam interview with a researcher. Patients will be [Read More]
Author: Dan Roberts
Opportunity to Participate in Paid Geographic Atrophy Study
Global Perspectives is looking for people with advanced dry AMD (age-related macular degeneration), also known as geographic atrophy (GA). The purpose of this study is to understand patients’ views and preferences related to treatments for geographic atrophy including some that are in development. No treatments will be administered in this study, as only opinions are [Read More]
Genentech to Reintroduce Susvimo for People With Wet AMD
The FDA has approved updates to Susvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks. Genentech announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States with wet, or neovascular, age-related [Read More]
Opportunity for People Affected by Geographic Atrophy
For persons with Geographic Atrophy due to Dry Age-related Macular Degeneration: Lagrippe Research is inviting three individuals diagnosed with Geographic Atrophy to participate in our upcoming discussion. We are also interested in speaking with family members / loved ones that assist and support people who have been diagnosed with GA. The research’s purpose is to [Read More]
Volunteers Needed for Participation in Dry AMD Seminar
On March 1, Dr. Todd Durham (Ph.D., Senior Vice President, Clinical & Outcomes Research, Foundation Fighting Blindness) will lead a dry AMD patient-focused drug development seminar. The online event is open to all (patients, families, professionals) and will include a panel of patients talking about their experiences with dry AMD. Volunteers for the panel are [Read More]